Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2025 | 7 | -$1.65 | -$0.99 | -$1.37 |
Q2 2025 | 3 | -$4.10 | $0.31 | -$1.34 |
Q3 2025 | 6 | -$3.73 | $0.28 | -$1.22 |
Q4 2025 | 5 | -$3.62 | $0.27 | -$1.19 |
Q1 2026 | 4 | -$3.43 | $0.26 | -$1.12 |
Q2 2026 | 3 | -$3.33 | $0.25 | -$1.09 |
Q3 2026 | 2 | -$1.95 | $0.15 | -$0.64 |
Q4 2026 | 2 | -$1.47 | $0.11 | -$0.48 |
CRISPR Therapeutics AG last posted its earnings results on Tuesday, November 5th, 2024. The company reported $-1.01 earnings per share for the quarter, topping analysts' consensus estimates of $-1.33 by $0.32. The company had revenue of 602,000 for the quarter and had revenue of 371.21 M for the year. CRISPR Therapeutics AG has generated $-2 earnings per share over the last year ($-1.94 diluted earnings per share) and currently has a price-to-earnings ratio of -13.65. CRISPR Therapeutics AG has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 17th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/05/2024 | Q3 2024 | -$1.33 | -$1.01 | 0.32 | $6.54 M | $602,000 |
08/05/2024 | Q2 2024 | -$1.37 | -$1.49 | -0.12 | $12.06 M | $517,000 |
05/08/2024 | Q1 2024 | -$1.63 | -$1.43 | 0.2 | $504,000 | |
02/21/2024 | Q4 2023 | -$0.07 | $1.12 | 1.19 | $200.00 M | |
11/06/2023 | Q3 2023 | -$1.98 | -$1.41 | 0.57 | $11.89 M | $0 |
08/07/2023 | Q2 2023 | -$2.18 | -$0.98 | 1.2 | $1.80 M | $70.00 M |
05/08/2023 | Q1 2023 | -$1.67 | -$0.67 | 1 | $100.00 M | |
02/21/2023 | Q4 2022 | -$2.32 | -$1.41 | 0.91 | $6,000 | |
11/01/2022 | Q3 2022 | -$2.30 | -$2.24 | 0.06 | $1.85 M | $94,000 |
08/08/2022 | Q2 2022 | -$2.23 | -$2.40 | -0.17 | $2.21 M | $158,000 |
05/09/2022 | Q1 2022 | -$1.91 | -$2.32 | -0.41 | $178,000 | |
02/15/2022 | Q4 2021 | -$1.74 | -$1.84 | -0.1 | $12.35 M | |
11/03/2021 | Q3 2021 | -$1.69 | -$1.67 | 0.02 | $1.23 M | $329,000 |
07/29/2021 | Q2 2021 | $3.52 | $10.01 | 6.49 | $900.19 M | $900.20 M |
04/27/2021 | Q1 2021 | -$1.45 | -$1.51 | -0.06 | $202,000 | |
02/16/2021 | Q4 2020 | -$1.23 | -$1.53 | -0.3 | $194,000 | |
10/28/2020 | Q3 2020 | -$1.17 | -$1.32 | -0.15 | $1.92 M | $148,000 |
07/27/2020 | Q2 2020 | -$0.92 | -$1.30 | -0.38 | $18.13 M | $44,000 |
04/28/2020 | Q1 2020 | -$1.09 | -$1.15 | -0.06 | $157,000 | |
02/12/2020 | Q4 2019 | -$0.63 | $0.53 | 1.16 | $77.02 M |
CRISPR Therapeutics AG has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, February 17th, 2025 based off last year's report dates.
In the previous quarter, CRISPR Therapeutics AG (:CRSP) reported $-1.01 earnings per share (EPS) to beat the analysts' consensus estimate of $-1.33 by $0.32.
The conference call for CRISPR Therapeutics AG's latest earnings report can be listened to online.
The conference call transcript for CRISPR Therapeutics AG's latest earnings report can be read online.
CRISPR Therapeutics AG (:CRSP) has a recorded annual revenue of $371.21 M.
CRISPR Therapeutics AG (:CRSP) has a recorded net income of $371.21 M. CRISPR Therapeutics AG has generated $-1.94 earnings per share over the last four quarters.
CRISPR Therapeutics AG (:CRSP) has a price-to-earnings ratio of -13.65 and price/earnings-to-growth ratio is -1.1.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED